Plasminogen Activator Inhibitor-1 Is the Primary Inhibitor of Tissue-Type Plasminogen Activator in Pregnancy Plasma

Summary

The aim of the present work was to clarify to what extent plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) contribute to the increase in plasma inhibition of tissue-type plasminogen activator (t-PA) observed during pregnancy. It was demonstrated that a monoclonal antibody against PAI-1 almost completely quenched inhibition of single-chain t-PA and most of the inhibition of two-chain t-PA in plasma during the third trimester of piegnancy. The remaining inhibition of two-chain t-PA was to a great extent abolished by a PAI-2 antibody. The second order rate constant (k₁) for inhibition of single-chain t-PA by the inhibitor neutralized by the PAI-1 antibody was about 4.8 · 10⁶ M^-1 · s^-1. The conversion of singlechain t-PA to the two-ehain form increased the reaction rate with the inhibitor about 3-fold. These kinetic data are compaiable with those obtained with TAI-l in non-pregnancy plasma oi with purified PAI-1. From the above results it is concluded that PAI-1 is the primary inhibitor of both single-chain and two chain t PA and that PAI-2 is the secondary inhibitor of two-chain t-PA in pregnancy plasma. The concentration of reactive PAI-1 versus gestation age was assayed in plasma from 6 women by binding of PAI-1 to ¹²⁵I-labelled single-chain t-PA followed by quantitation of the labelled t-PA-PAI-1 complex after separation by SDS- polyacrylamide gel electrophoresis. It was found that the concentration of PAI-1 increased 4 to 8-fold during the gestation period reaching a level of about 1.4 nM at term. Post partum the plasma concentration declined abruptly within 24 h to the level observed in age-matched non-pregnant women.

Keywords

Plasma - Plasminogen activator inhibitor-1 - Plasminogen activator inhibitor-2 - Pregnancy - Tissue-type plasminogen activator

• References

• 1 Bonnar J. Haemostasis and coagulation disorders in pregnancy. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (Eds.), pp. 454-471 Churchill Livingstone; Edinburgh, London, Melbourne, New York: 1981
• 2 Woodfield DG, Cole SK, Cash JD. Impaired fibrinolytic response to exercise stress in normal pregnancy. Its possible role in the development of Shwartzman-type reactions. Am J Obst Gynec 1968; 102: 440-446
• 3 Bonnar J, McNicoI GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3: 387-389
• 4 Åstedt B, Isacson S, Nilsson IM, Pandolfi M. Fibrinolytic activity of veins during pregnancy. Acta Obst Gynec Scand 1970; 49: 171-173
• 5 Åstedt B. Significance of placenta in depression of fibrinolytic activity during pregnancy. J Obst Gynec Br Commonw 1972; 79: 205-206
• 6 Müllertz S. Fibrinolysis: An overview. Sem Thromb Haemostas 1984; 10: 1-5
• 7 Danø K, Andreasen PA, Grpndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cane Res 1985; 44: 139-266
• 8 Bachmann F, Kruithof E KO. Tissue plasminogen activator: Chemical and physiological aspects. Sem Thromb Haemostas 1984; 10: 6-17
• 9 Brakman P, Astrup T. Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis. Scand J Clin Lab Invest 1963; 15: 603-609
• 10 Thorsen S. The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects. Scand J Clin Lab Invest 1973; 31: 51-59
• 11 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
• 12 Kruithof E KO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
• 13 van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
• 14 Philips M, Juul A-G, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
• 15 Sprengers ED, Verheijen JH, van Hinsbergh V WM, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163-170
• 16 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator- inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor. Biochim Biophys Acta 1984; 802: 111-118
• 17 Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-3647
• 18 Sprengers ED, Princen H MG, Kooistra T, van Hinsbergh V WM. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-758
• 19 Holmberg L, Lecander I, Persson B, Åstedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-137
• 20 Åstedt B, Lecander I, Brodin T, Lundblad A, Low K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemostas 1985; 53: 122-125
• 21 Philips M, Juul A-G, Thorsen S, Selmer J, Zeuthen J. Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemostas 1986; 55: 213-217
• 22 Kruithof E KO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69: 460-466
• 23 Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221-228
• 24 Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-126
• 25 Aznar J, Gilabert J, Estellés A, Espana F. Fibrinolytic activity and Protein C in preeclampsia. Thromb Haemostas 1986; 55: 314-317
• 26 Jprgensen M, Philips M, Thorsen S, Selmer J, Zeuthen J. The fastacting inhibitor of tissue plasminogen activator (t-PA) in pregnancy plasma is of the endothelial type. Fibrinol 1986; abstract no 54.
• 27 Petersen LC, Handest P, Brender J, Selmer J, Jørgensen M, Thorsen S. A sensitive solid-phase immunosorbent assay for tissue-type plasminogen activator activity in plasma using trinitrobenzoylated poly-D-lysine as a stimulator for plasminogen activation. Thromb Haemostas 1987; 57: 205-211
• 28 Petersen LC, Suenson E. Trinitrobenzoylated poly (D-lysine) as a stimulator of interactions between plasminogen, plasmin, and tissue- type plasminogen activator. Biochim Biophys Acta 1986; 883: 313-325
• 29 Wallen P, Bergsdorf N, Ranby M. Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin. Biochim Biophys Acta 1982; 719: 318-328
• 30 Jørgensen M, Mortensen JZ, Madsen AG, Thorsen S, Jacobsen B. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis. Scand J Haematol 1982; 29: 217-223
• 31 Weber K, Osborn M. Proteins and sodium dodecyl sulphate : molecular weight determination on polyacrylamide gels and related procedures. In: The Proteins. Neuraih H, Hill RL. (Eds.) Academic Press; New York, San Francisco, London: vol. 1 1975. pp. 179-223
• 32 Jørgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-180
• 33 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
• 34 Kruithof E KO, Tran-Thang C, Bachmann F. The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemostas 1986; 55: 65-69
• 35 Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of the reaction between tissue-type (t-PA) or urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor of type 1 (PAI1) or type 2 (PAI 2). Osaka Symposium on Fibrinolysis, September 24th, 1986; abstract volume
• 36 Astedt B, Bladh B, Christensen U, Lecander I. Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. Scand J Clin Lab Invest 1985; 45: 429-435
• 37 Kruithof E KO, Vassalli J-D, Schleuning W-D, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U 937. J Biol Chem 1986; 261: 11207-11213
• 38 Haggroth L, Mattsson C, Felding P, Nilsson IM. Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women. Thromb Res 1986; 42: 585-594
• 39 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New Eng J Med 1985; 313: 1557-1563
• 40 Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary disease. Br Med J 1985; 291: 573-574
• 41 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
• 42 Korninger C, Collen D. Neutralization of human extrinsic (tissue- type) plasminogen activator in human plasma: No evidence for a specific inhibitor. Thromb Haemostas 1981; 46: 662-665
• 43 Ranby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 1982; 27: 175-183
• 44 Kluft C, Jie A FH, Sprengers ED, Verheijen JH. Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Lett 1985; 190: 315-318
• 45 Sprengers ED. A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma. Thromb Haemostas 1986; 55: 74-77